Transgene and Randox to develop oncolytic treatment for solid tumours


Transgene has a partnered with in-vitro diagnostics company Randox to combine their technologies and develop multifunctional oncolytic immunotherapies. 

New oncolytic viruses (OVs) resulting from the current partnership will use Transgene’s latest viral platform Invir.IO, with one or more of Randox’s single-domain antibodies (SdAbs) will be vectorised. 

Advanced immunotherapies will help combine the oncolytic effect of the viruses with properties of the vectorised SdAbs that will be locally expressed in the tumour microenvironment (TME) with the focus on treating patients with immunosuppressed solid tumours. 

Randox Laboratories founder and managing director Dr Peter FitzGerald said: "We are looking forward to working with Transgene to generate OVs that will be able to express multiple functions directly into a tumour, enhancing their efficacy. 

"This partnership will allow us to better leverage our SdAb capabilities and immuno-oncology expertise and add to our strategic collaborations across the world." 

"This partnership will allow us to better leverage our SdAb capabilities and immuno-oncology expertise and add to our strategic collaborations across the world."

Under the deal, Transgene will create new anticancer oncolytic virus (OV) drugs by using its Vaccinia virus (TK-, RR-) strain, and its skill in molecular engineering and translational research.

The new viral strain provides increased oncolytic properties and its large genome capacity allows multiple therapeutic payloads (anticancer weapons) to be delivered in a tumour, where the virus replicates.

In addition, Randox will offer expertise in antibody engineering and provide access to its collection of new and future immunotherapeutic SdAbs to be used as vectorised payloads.

The SdAbs will be able to modulate the patient’s immune response and generate a synergistic effect with Transgene’s oncolytic viral platform.